---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-050499"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:29:21.841548+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC

## Summary
- FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.
- New dosing aims to reduce medication errors and non-allergic anaphylactoid reactions (NAARs) without compromising efficacy.
- Acetadote indicated to prevent/lessen liver injury after acetaminophen overdose, the leading cause of acute liver failure in the US.
- Cumberland Pharmaceuticals (CPIX) specialty pharma; CEO A.J. Kazimi highlighted commitment to improving patient care.

## SEC filing metadata
- accession: 0001628280-24-050499
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/0001628280-24-050499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/cpix-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-050499
- JSON: https://secwatch.observer/filing/0001628280-24-050499.json
- Plain text: https://secwatch.observer/filing/0001628280-24-050499.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.